Amgen To Rapidly Move Olpasiran Into Phase III For Lp(a) Reduction

The siRNA drug demonstrated a significant reduction in lipoprotein(a) from baseline of up to or greater than 90% for the majority of doses in a Phase II trial; Novartis has a potential first-to-market advantage.